Patents by Inventor Laykea Tafesse

Laykea Tafesse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrimidines as sodium channel blockers
    Patent number: 9163008
    Abstract: The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A1, X, A2, W1, W2, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: October 20, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Chiyou Ni, Bin Shao, Laykea Tafesse, Jiangcho Yao, Mark Youngman, Minnie Park
  • Heterocyclic compounds
    Patent number: 9156830
    Abstract: The invention relates to compounds of Formula I: wherein Ar1, Ar2, Ar3, L1, L2, Y, Z and v are defined in the specification, and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: October 13, 2015
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Noriyuki Kurose, Yasuyoshi Iso, Naoko Yamaguchi, Bin Shao, Laykea Tafesse, Xiaoming Zhou, Jianming Yu
  • INDOLE DERIVATIVES AND USE THEREOF
    Publication number: 20150284383
    Abstract: The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1e, R1f, A, X, Y, Z, and W4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 8, 2015
    Inventors: Stephen M. Lynch, Jiangchao Yao, Jae Hyun Park, Laykea Tafesse
  • PYRIDINE COMPOUNDS AND THE USES THEREOF
    Publication number: 20150259293
    Abstract: The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: May 28, 2015
    Publication date: September 17, 2015
    Inventors: Chiyou Ni, Bin Shao, Laykea Tafesse, Jiangchao Yao, Jianming Yu, Xiaoming Zhou
  • QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS
    Publication number: 20150250789
    Abstract: The invention relates to aryl substituted quinazolines of Formula I, and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, A, and R1-R4 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: May 19, 2015
    Publication date: September 10, 2015
    Inventors: R. Richard Goehring, Laykea Tafesse, Jiangchao Yao
  • Pyridine compounds as sodium channel blockers
    Patent number: 9120752
    Abstract: The invention relates to substituted pyridine compounds of Formula I: (I) or a pharmaceutically acceptable salt, prodrug, or solvate thereof wherein A1, X, A2, R1a, R1b, R1c, G, and z are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: September 1, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Donald J. Kyle, Chiyou Ni, Minnie Park, Laykea Tafesse
  • BENZOMORPHAN COMPOUNDS AS OPIOID RECEPTORS MODULATORS
    Publication number: 20150210646
    Abstract: The present invention is directed to Benzomorphan Analog compounds of the Formula (I), Formula (IA), Formula (IB), Formula (IC), or Formula (ID) as shown below, wherein R1, R2a, R2b, R3, R4, Z, and G are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
    Type: Application
    Filed: May 10, 2013
    Publication date: July 30, 2015
    Inventors: Jae Hyun Park, David Rosen, Laykea Tafesse, Jianming Yu
  • PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS
    Publication number: 20150203494
    Abstract: The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein , R1a-R3a, R4, Y and Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: January 28, 2015
    Publication date: July 23, 2015
    Inventors: Jeffrey LOCKMAN, Laykea Tafesse, Mark A. Youngman
  • SPIROCYCLIC MORPHINANS AND THEIR USE
    Publication number: 20150203495
    Abstract: The application is directed to compounds of Formula I?-A and especially to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein R1a-R5a, Y, Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I?-A, and especially compounds of Formula I-A, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: January 28, 2015
    Publication date: July 23, 2015
    Inventors: R. Richard GOEHRING, Laykea Tafesse, Mark A. Youngman
  • BUPRENORPHINE ANALOGS
    Publication number: 20150203504
    Abstract: The present invention is directed to Buprenorphine Analog compounds of Formula I, II, III, IV or V and including various stereoisomers (such as Formula IA shown below), wherein R1, R3a, R3b, R16, R15, G, Q, X, A and Z are as defined herein. Compounds of the Invention may be useful for preparing medicaments useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors. Compounds of the Invention may be useful for treating Conditions such as pain, constipation, and others modulated by activity of opioid and ORL-1 receptors.
    Type: Application
    Filed: January 20, 2015
    Publication date: July 23, 2015
    Inventors: R. Richard Goehring, Laykea Tafesse, Jeffrey Lockman
  • DIBENZAZEPINE DERIVATIVES AND USE THEREOF
    Publication number: 20150175569
    Abstract: The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R3a, R3b, R6, V1, V2, Z1, Z2, Z3, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.
    Type: Application
    Filed: November 25, 2014
    Publication date: June 25, 2015
    Inventors: Stephen M. Lynch, Laykea Tafesse
  • Substituted Morphinans and the Use Thereof
    Publication number: 20150175571
    Abstract: The application is directed to compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: December 19, 2014
    Publication date: June 25, 2015
    Inventors: Andrew KASSICK, Jeffrey LOCKMAN, Laykea TAFESSE
  • Benzomorphan analogs and the use thereof
    Patent number: 9056836
    Abstract: The present invention is directed to Benzomorphan Analog compounds of the Formula I-ID as shown below, wherein R1, R2a, R2b, R3 and R4 are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: June 16, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Jeffrey Lockman, Jae Hyun Park, Laykea Tafesse, Jiangchao Yao, Jianming Yu
  • Pyridine compounds and the users thereof
    Patent number: 9056832
    Abstract: The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: June 16, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Chiyou Ni, Bin Shao, Laykea Tafesse, Jiangchao Yao, Jianming Yu, Xiaoming Zhou
  • Quinazoline compounds as sodium channel blockers
    Patent number: 9045435
    Abstract: The invention relates to aryl substituted quinazolines of Formula I, and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, A, and R1-R4 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: June 2, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: R. Richard Goehring, Laykea Tafesse, Jiangchao Yao
  • BENZIMIDAZOLE DERIVATIVES AND USE THEREOF
    Publication number: 20150133500
    Abstract: The invention provides compounds that are useful as sodium channel blockers. In one aspect, the invention provides compounds of Formula I: and pharmaceutically acceptable salts, solvates, hydrates, or diastereomers thereof, wherein W1, W2, W3, W4, U, G, m, R1, and R2 are defined in the disclosure. In certain embodiments, the invention provides compounds of Formulae II to V as set forth supra. The invention also provides the use of compounds of any of the above discussed formulae to treat a disorder responsive to blockade of sodium channels. In one embodiment, Compounds of the Invention are useful for treating pain.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 14, 2015
    Inventors: Laykea Tafesse, Jiangchao Yao, Xiaoming Zhou
  • 4-phenylsulfonamidopiperidines as calcium channel blockers
    Patent number: 9000174
    Abstract: The invention relates to piperidinyl compounds of Formula (I): or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R1-R3 and Z are defined as set forth in the specification. The invention is also directed to an assay useful for identifying such compounds as N-type calcium channel modulators or blockers. The invention is also directed to the compounds of Formula (I) and compounds identified by the above assay, and the use of such compounds to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: April 7, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Elfrida R. Benjamin, Zhengming Chen, Deyou Sha, Laykea Tafesse, Samuel F. Victory, John W. F. Whitehead
  • Spirocyclic morphinans and their use
    Patent number: 8987287
    Abstract: The application is directed to compounds of Formula I?-A and especially to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein R1a-R5a, Y, Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I?-A, and especially compounds of Formula I-A, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: March 24, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: R. Richard Goehring, Laykea Tafesse, Mark A. Youngman
  • Pyridonemorphinan analogs and biological activity on opioid receptors
    Patent number: 8980906
    Abstract: The application is directed to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein , R1a—R3a, R4, Y and Za are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I-A to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: March 17, 2015
    Assignee: Purdue Pharma L.P.
    Inventor: Laykea Tafesse
  • Buprenorphine analogs
    Patent number: 8969358
    Abstract: The present invention is directed to Buprenorphine Analog compounds of Formula I, II, III, IV or V and including various stereoisomers (such as Formula IA shown below), wherein R1, R3a, R3b, R16, R15, G, Q, X, A and Z are as defined herein. Compounds of the Invention may be useful for preparing medicaments useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors. Compounds of the Invention may be useful for treating Conditions such as pain, constipation, and others modulated by activity of opioid and ORL-1 receptors.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: March 3, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Richard Goehring, Laykea Tafesse, Jiangchao Yao